A study published in the 'Journal of the American Medical Association' (JAMA) has demonstrated the safety and effectivecompared to the basal data obtained with the use of sensor pumps.
"This great internal study showed that the participants who had the Medtronic Hybrid closed handle system had a better glucose control and did not demonstrate security problems. During the study phase, there were no episodes of severe hypoglycemia or ketoacidosis inPatients with type 1 diabetes followed by therapy, "explained the main investigator of the work and executive director of the International Diabetes Center in Minneapolis (United States), Richard M. Bergenstal.
The data, they continue, are "convincing" and demonstrate that the ability of the system to dose insulin automatically 24 hours a day can impact patients' lives, especially at night, when it is "more complicated"Maintain the desired glucose levels.
The study on the Medtronic Hybrid closed handle system is the first key trial in the United States of closed handle technology, and the largest local study on closed handle, with an evaluation that includes more than 12,000 days.The system automates basal insulin infusion in order to maintain glucose levels in the target range as long as possible during the day and night.
This multicenter study included 124 people with type 1 diabetes with a minimum age of 14 years in 10 centers (nine of the United States and one of Israel), who were asked to introduce the carbohydrates they ingented and the information about theexercise that they practiced and that they calibrate the sensor periodically.
"We are delighted with the progress that we have achieved in the automation of the infusion of basal insulin and the fact that each new advance in our process simplifies the control of diabetes and offers greater automation and more tranquility. We have the commitment to develop solutionsSignificant as this to offer greater freedom and a better health, so that people with diabetes and their caregivers can devote less time to control diabetes and more time to enjoy the day to day, "said the president of Intensive Insulin Management DiabetesIn Medtronic, Alejandro Galindo.
